Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine whether further research is warranted to assess whether
tofacitinib is an effective steroid sparing treatment for pulmonary sarcoidosis. The primary
endpoint for this study is a 50% or greater reduction in corticosteroid requirement.